These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 17968912)
1. Why publish a secondary analysis of only one treatment group in the Behandelstrategieën voor Reumatoide Artritis trial? Comment on the article by van der Bijl et al. Boers M Arthritis Rheum; 2007 Nov; 56(11):3876; author reply 2876-7. PubMed ID: 17968912 [No Abstract] [Full Text] [Related]
2. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Verpoort KN; Schreuder GM; Ewals JA; Terwiel JP; Ronday HK; Kerstens PJ; Toes RE; de Vries RR; Breedveld FC; Dijkmans BA; Huizinga TW; Allaart CF Arthritis Rheum; 2008 May; 58(5):1293-8. PubMed ID: 18438829 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of intraarticular infliximab administration in patients with recurrent gonarthritis: comment on the article by van der Bijl et al. Drosos AA Arthritis Care Res (Hoboken); 2010 Feb; 62(2):291; author reply 291-2. PubMed ID: 20191533 [No Abstract] [Full Text] [Related]
4. Autoimmune diseases. The B cell slayer. Matthews R Science; 2007 Nov; 318(5854):1232-3. PubMed ID: 18033858 [No Abstract] [Full Text] [Related]
5. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials. Doyle MK; Rahman MU; Han C; Han J; Giles J; Bingham CO; Bathon J Semin Arthritis Rheum; 2009 Oct; 39(2):123-31. PubMed ID: 18823645 [TBL] [Abstract][Full Text] [Related]
6. Monitoring guidelines for methotrexate-treated rheumatoid arthritis patients: comment on the article by Yazici et al. Alarcón GS; Kremer J; Weinblatt M Arthritis Rheum; 2004 Aug; 50(8):2710; author reply 2710-1. PubMed ID: 15334490 [No Abstract] [Full Text] [Related]
7. Trials in rheumatoid arthritis: choosing the right outcome measures--comment on the article by Felson et al. Porter D Ann Rheum Dis; 2008 Sep; 67(9):1356. PubMed ID: 18697785 [No Abstract] [Full Text] [Related]
8. Reponse to methotrexate and reduced mortality in patients with rheumatoid arthritis: comment on the article by Krause et al. Alarcón GS Arthritis Rheum; 2000 Aug; 43(8):1902-3. PubMed ID: 10943886 [No Abstract] [Full Text] [Related]
9. The clinical relevance of a prediction rule for disease outcome in patients with undifferentiated arthritis: comment on the article by van der Helm-van Mil et al. Visser H; Hazes JM; Luime J Arthritis Rheum; 2009 Jul; 60(7):2208-9; author reply 2209-10. PubMed ID: 19565508 [No Abstract] [Full Text] [Related]
10. Limitations of the study of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: comment on the article by Braun et al. Raghu P; Grover PS; Kumar A Arthritis Rheum; 2008 Jul; 58(7):2209; author reply 2209-10. PubMed ID: 18576338 [No Abstract] [Full Text] [Related]
11. Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate. Owczarczyk K; Hellmann M; Fliedner G; Röhrs T; Maizus K; Passon D; Hallek M; Rubbert A Ann Rheum Dis; 2008 Nov; 67(11):1648-9. PubMed ID: 18854518 [No Abstract] [Full Text] [Related]
12. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Durez P; Malghem J; Nzeusseu Toukap A; Depresseux G; Lauwerys BR; Westhovens R; Luyten FP; Corluy L; Houssiau FA; Verschueren P Arthritis Rheum; 2007 Dec; 56(12):3919-27. PubMed ID: 18050189 [TBL] [Abstract][Full Text] [Related]
13. A novel approach to the development of anti-inflammatory agents: adenosine release at inflamed sites. Cronstein BN J Investig Med; 1995 Feb; 43(1):50-7. PubMed ID: 7719759 [No Abstract] [Full Text] [Related]
15. Lymphomatoid granulomatosis in a patient with rheumatoid arthritis receiving methotrexate: successful treatment with the anti-CD20 antibody mabthera. Schalk E; Krogel C; Scheinpflug K; Mohren M Onkologie; 2009 Jul; 32(7):440-1. PubMed ID: 19556825 [No Abstract] [Full Text] [Related]
16. [Biopharmaceuticals in the treatment of rheumatoid arthritis]. Baslund B; Bendtzen K Ugeskr Laeger; 2008 Jun; 170(24):2108-10. PubMed ID: 18572481 [TBL] [Abstract][Full Text] [Related]
17. Long term treatment of rheumatoid arthritis with rituximab. Caporali R; Caprioli M; Bobbio-Pallavicini F; Bugatti S; Montecucco C Autoimmun Rev; 2009 Jun; 8(7):591-4. PubMed ID: 19393205 [TBL] [Abstract][Full Text] [Related]
18. Abatacept: new drug. Rheumatoid arthritis: after failure of TNF alpha antagonists and rituximab. Prescrire Int; 2008 Dec; 17(98):232. PubMed ID: 19422143 [No Abstract] [Full Text] [Related]
19. Methotrexate polyglutamate concentrations and association with disease control in rheumatoid arthritis: comment on the article by Stamp et al. Dervieux T; Kremer J Arthritis Rheum; 2010 Aug; 62(8):2559-60; author reply 2560-1. PubMed ID: 20506252 [No Abstract] [Full Text] [Related]
20. Short-term effects of rituximab on flow-mediated dilatation may be mediated by intravenous glucocorticoids: comment on the article by Gonzalez-Juanatey et al. Sandoo A; Toms T; Zanten JV; Carroll D; Kitas G Arthritis Rheum; 2009 Jun; 61(6):854-5; author reply 855-6. PubMed ID: 19479694 [No Abstract] [Full Text] [Related] [Next] [New Search]